Squarepoint Ops LLC Grows Stake in Janux Therapeutics, Inc. (NASDAQ:JANX)

Squarepoint Ops LLC grew its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 155.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 41,176 shares of the company's stock after buying an additional 25,034 shares during the quarter. Squarepoint Ops LLC owned 0.08% of Janux Therapeutics worth $2,205,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Russell Investments Group Ltd. boosted its holdings in shares of Janux Therapeutics by 77.7% in the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock worth $54,000 after buying an additional 442 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of Janux Therapeutics by 1.6% during the 4th quarter. Rhumbline Advisers now owns 38,153 shares of the company's stock worth $2,043,000 after acquiring an additional 599 shares during the last quarter. Kennedy Capital Management LLC grew its position in shares of Janux Therapeutics by 7.9% during the 4th quarter. Kennedy Capital Management LLC now owns 12,713 shares of the company's stock valued at $681,000 after acquiring an additional 928 shares during the period. MetLife Investment Management LLC increased its stake in shares of Janux Therapeutics by 5.8% in the 4th quarter. MetLife Investment Management LLC now owns 17,298 shares of the company's stock worth $926,000 after purchasing an additional 949 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Janux Therapeutics by 10.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,128 shares of the company's stock worth $596,000 after purchasing an additional 1,095 shares during the period. 75.39% of the stock is owned by institutional investors.

Insider Buying and Selling at Janux Therapeutics

In other Janux Therapeutics news, Director Ra Capital Management, L.P. bought 341,742 shares of the business's stock in a transaction that occurred on Wednesday, March 5th. The stock was purchased at an average cost of $30.64 per share, with a total value of $10,470,974.88. Following the completion of the acquisition, the director now owns 9,658,988 shares in the company, valued at $295,951,392.32. This trade represents a 3.67% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Andrew Hollman Meyer sold 3,334 shares of the company's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $30.00, for a total transaction of $100,020.00. Following the sale, the insider now directly owns 82,139 shares in the company, valued at approximately $2,464,170. The trade was a 3.90% decrease in their position. The disclosure for this sale can be found here. Insiders own 8.10% of the company's stock.

Analysts Set New Price Targets

Several research firms have issued reports on JANX. Wedbush reissued an "outperform" rating and set a $76.00 price target (up previously from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. Scotiabank reduced their target price on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a report on Friday, February 28th. Finally, HC Wainwright restated a "buy" rating and set a $70.00 target price on shares of Janux Therapeutics in a research note on Monday, March 3rd. One analyst has rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $95.25.

Janux Therapeutics Stock Performance

JANX traded up $1.21 during trading on Monday, reaching $25.01. 853,655 shares of the company traded hands, compared to its average volume of 884,360. The company has a market cap of $1.48 billion, a P/E ratio of -21.38 and a beta of 3.24. Janux Therapeutics, Inc. has a 12-month low of $22.48 and a 12-month high of $71.71. The firm has a fifty day simple moving average of $27.27 and a 200 day simple moving average of $38.33.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.05. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. As a group, sell-side analysts expect that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.